Skip to main content

Table 2 Demographic and clinical characteristics of the studied groups

From: Effects of gonadotropin-releasing hormone agonist (GnRH-a) as luteal phase support in intracytoplasmic sperm injection (ICSI) cycles: a randomized controlled trial

Characteristics

Group

pvalue

GnRH agonist

Placebo

Number of patients

122

118

Age (years)

31.77 ± 4.57

32.11 ± 5.05

NS

BMI

25.63 ± 3.13

25.89 ± 4.01

NS

Duration of infertility (years)

3.9 ± 2.4

4.1 ± 1.6

NS

Type of infertility (primary), (%)

83.8

79.7

NS

Type of infertility (secondary), (%)

16.2

20.3

NS

Number of previous ICSI or IVF-ET

2.5 ± 0.4

2.2 ± 0.6

NS

FSH (day 3) (mIU/ml)

6.9 ± 3.1

7.1 ± 2.4

NS

AMH (ng/ml)

3.15 ± 2.55

3.74 ± 2.15

NS

Sperm (count/ml)

(59 ± 41) × 106

(55 ± 39) × 106

NS

  1. AMH anti-Mullerian hormone, BMI body mass index, FSH follicle-stimulating hormone, NS non-significant